As AbbVie’s Humira faces copycat biologics, the biggest beneficiaries will be middlemen trading and distributing the drugs such as Cigna and CVS.
wsj
Not all news on the site expresses the point of view of the site, but we transmit this news automatically and translate it through programmatic technology on the site and not from a human editor.
